Pseudomonas aeruginosa. Vacunas: un reto a la investigación.
Pseudomonas aeruginosa. Vaccines: a challenge to research.
Sara C. Esnard, Aniel Moya, Barbara Cedré, Tania Valmaseda, Yadira Pino Navarro, Gustavo Sierra González.
Instituto Finlay. Centro de Investigación-Producción de Vacunas y Sueros. Ciudad de La Habana. Cuba. E-mail: scesnard@finlay.edu.cu
RESUMEN
Pseudomonas aeruginosa, patógeno gramnegativo versátil y oportunista debido a su gran adaptabilidad fisiológica, potencial metabólico y mecanismos de virulencia, es causa frecuente a escala mundial de severas o letales infecciones en pacientes hospitalizados. El empeño por lograr terapias alternativas para prevenir o combatir las infecciones producidas por P. aeruginosa ha ocupado a investigadores de todo el mundo desde la segunda mitad del pasado siglo y actualmente se continúan reportando trabajos que respaldan los ensayos de candidatos vacunales, fundamentalmente a partir de antígenos proteicos, mayoritariamente basados en la construcción de vacunas recombinantes. En este artículo se presenta una revisión de trabajos publicados sobre las investigaciones desarrolladas en diferentes países, con el objetivo de obtener candidatos vacunales para la prevención o tratamiento de las infecciones causadas por Pseudomonas aeruginosa, a partir de la década de los años 50 del siglo XX hasta el 2003.
ABSTRACT
Pseudomonas aeruginosa is a gram-negative pathogen, versatile and opportunistic in terms of their physiological and metabolic potential and virulence mechanisms, which is a frequent cause of severe or lethal infections in hospitalized patients over the world The aim to achieve alternative therapies to prevent or combat the infections caused by P. aeruginosa has occupied investigators from all the world since the second half of last century and at the moment works have been reported that support assays of vaccine candidates, starting mainly from protein antigens and based on the construction of recombinant vaccines. In this article a review of published works on research developed in different countries with the purpose to obtain vaccine candidates for the prevention or treatment of the infections caused by Pseudomonas aeruginosa beginning since the decade of the fifties of the 20th century up to the year 2003.
Keywords: Pseudomonas aeruginosa, vaccine candidates.
Texto completo formato PDF
REFERENCIAS
1. Kiska DL and Gilligan H. Pseudomonas. En: Murria P R; Baron E J; Pfaller M A; Tenover F C y Yolken R H. eds. Manual of Clinical Microbiology 7th Edition. American Society for Microbiology, Washington DC; 1999:517-25.
2. Microbiología Médica 15t Edición, 1966. En Jawetz, Melnick y Adelberg. G.F. Brooks, J.S. Butel y L.N. Ornston eds. Editorial El Manual Moderno, S. A. de C. V. México, DF.:265-72. 1996.
3. Pruit BA, Mc.Manus AT, Kim SH y Goodwing CW. Burn Wound Infections: Current Status. World J. Surg. 1998; 22:135-145.
4. Rosenfeld M, Emerson J y Accurso F. Diagnostic accurate of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr. Pulmonol. 1999; 28:323-28.
5. Rosenstein BJ y Zetlin PL. Cystic Fibrosis. Lancet, 1998; 331(9098):227-82.
6. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?. Clin.Infect. Dis. 2000; 34:634-40.
7. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR y Wiener-Kronish JP. Pathogenesis of septic shock in Pseudomonas aeruginosa. J Clin Invest. 1999;104:743-50.
8. Azghani AO, Miller EJ y Patterson BT. Virulence factors from Pseudomonas aeruginosa increase lung epithelial permeability. Lung., 2000; 178:261- 69.
9. Tang HB, Di Mango E, Brian R, Gambelio M, Iglewski B, Goldberg JB y Prince A. Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Infect Immun. 1996; 64:37-43.
10. The Jordan Report. Annual Report. Accelerated Development of Vaccines. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 1995:21-23.
11. Rosenthal SM, Millican RC y Rust J. A factor in human ã globulin preparations active against Pseudomonas aeruginosa infections. Proc. Soc. Exper. Biol. Med. 1957; 94:214-17.
12. Holder IA. Pseudomonas immunotherapy. Review article. Serodiagnostic and Immunotherapy. 1988; 2:7-16.
13. Alms TH y Bass JA. Induction of protection by an alcohol-precipitated fraction from the slime layer. J Infect Dis. 1967.117:249-56.
14. Markley K y Smallman E. Protection by vaccination against Pseudomonas infection after thermal injury. J Bacterio. 1968. 96:867-74.
15. Alexander JW, Fisher MW, Mc.Millan BG y Alteimer WA. Prevention of invasive Pseudomonas infection in burns with a new vaccine. Arch Surg. 1969. 99:249-56.
16. Miller JM, Spilsbury JF, Jones RJ, Roe EA y Lowsbury EJL. A new polyvalent Pseudomonas vaccine. J Med Microbiol. 1977;10:19-27.
17. Young LS, Meyer RD y Amstrong D. Pseudomonas aeruginosa vaccine in cáncer patients. Am Intern Med. 1973;79:518-27.
18. Polk HC Jr, Borden S y Alderete JA. Prevention of Pseudomonas respiratory infection in a surgical intensive care unit. Am Surg. 1973. 177:607-15.
19. Pennington JE. Immunotherapy of Pseudomonas aeruginosa infection. En: Doggert RE ed. Pseudomonas aeruginosa clinical manifestations of infection and current therapy. New York Academic Press. 1976;192-215.
20. Pennington JE, Pier GB. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia. Rev Infect Dis. 1983. 5:5852-57.
21. Pennington JE, Hickey WF, Blackwood LL y Arnaut MA. Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest. 1981; 68:1140-48.
22. Cryz SJ, Furer E y Germainer R. Protection against fatal Pseudomonas aeruginosa burn sepsis by immunization with lipopolysaccharide and high – molecular weigth polysaccharide. Infect. Immun. 1984;43:795-9.
23. Cryz SJ, Jr., Fürer J, Sadoff R, Germainer L, Pastan I, Willingham MC y Fitzgerald DJP. Use of Pseudomonas aeruginosa Toxin A in the construction of conjugate vaccines and inmunotoxins. Rew. Infect. Dis. 1987. 9(3):644-49.
24. Cryz SJ, Lang AB, Sadoff JC, Germainer R y Fürer E. Vaccine potential of Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugates. Infect. Immun. 1987; 55(7):1547-51.
25. Cryz SJ, Sadoff JC, Ohmann D y Fürer E. Characterization of the human immune response to a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine. J Lab Clin Med. 1988.111:701-07.
26. Saad UB, Lang AB, Wedgwood J, Rüdeberg A, Que JU, Fürer E y Cryz SJ. Safety and inmunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet. 1991. 338:1236-37.
27. Cryz SJ, Wedgwood J, Lang AB, Rüdeberg A, Que JU, Fürer E y Schaad UB. 1994. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis 169:1159-62.
28. Lang AB, Schaad UB, Rüdeberg A, Wedgwood J, Que JU, Fürer E y Cryz SJ. 1995. Effect of high affinity anti- Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatrics 127:711-17.
29. Cryz SJ, Lang AB, Rüdeberg A, Wedgwood J, Que JU, Fürer E y Schaad UB. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine. Behring Inst Mitt. 1997. 98:345-49.
30. Berna Biotech AG. AERUGEN. http:/www.bernabiotech.com/rd/literature/aerugen/ 2003.
31. Berna Biotech AG: News. BernaBiotech’s Aerugen Granted Orphan Drug Designation in the USA.
32. http:/www.bernabiotech.com/news/archive/artivcl e/20020515 01.htlm
33. Liu PV, Matsumoto H, Kusuma H y Bergan T. Survey of heat-stable, major somatic antigens. Acta Microbiol. Acad.Sci. Hung. 1983.13:295-318.
34. Mathews-Greer JM y Gilleland HE Jr. Outer Membrane Protein F (Porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. The Journal Infect. Dis. 1987. 155(6):1282-91.
35. Gilleland HE. Jr, Gilleland LB y Mathews-Greer JM. Outer Membrane Protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect. Immun. 1988. 56(5):1017-22.
36. Lanyi B. Serological properties of Pseudomonas aeruginosa type-specific thermolabile (flagellar) antigens. Acta Microbiol Acad Sci Hung. 17:35-48.
37. Crowe B, Enzersberger O, Schober-Bendixen S, Mitterer A, Mundt W, Livey I, Pabst H, Kaeser R, Eibl M, Eibl J y Dorner F. 1991. The first clinical tryal of Immuno’s experimental Pseudomonas aeruginosa flagerllar vaccines. En: Homma JY, Tanimoto H, Holder IA, Hoiby N, Döring G (eds): Pseudomonas aeruginosa in Human Diseases. Antibiot Chemother. Basel Karger vol 44:141-56.
38. Döring G y Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst. Mitt. 1997; 98:338-344.
39. Gilleland HE. Jr, Gilleland LB y Mathews-Greer JM. 1988. Outer Membrane Protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect. Immun. 56(5):1017-22.
40. Duchene M, Barron C, Schweizer A, von Specht B y Domdey H. 1989. Pseudomonas aeruginosa outer membrane lipoprotein I. Molecular cloning, primary structure and expresión in Escherichia coli. J. Bacteriol. 171, 4130-37.
41. Finke M, Duchéne M, Eckhardt A, Domdey H y von Specht B. 1990. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expresed in Escherichia coli. Infect. Immun. 58: 2241-44.
42. Funke M, Muth G, Reichhelm T, Thoma M, Duchene M, Hungerer K, Domdey H y von Specht B. Protection of immunosuppresed mice against infection with Pseudomonas aeruginosa by recombinant aeruginosa lipoprotein I and lipoprotein-specific monoclonal antibodies. Infect. Immun. 1991; 59:1251-54.
43. Hughes E y Gilleland HE Jr. Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P.aeruginosa infection in a murine acute pneumonia model. Vaccine. 1995; 13(18):1750-53.
44. von Specht BU, Knapp B, Muth G, Hungerer KD, Lücking C, Schmitt A y Domdey H. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidate. Journal of Biothecnology, 1966; 44:145-53.
45. Gilleland HE Jr., Gilleland L, Staczek J, Harty R, García-Sastre A, Engelhardt O y Palese P. Chimeric Influenza viruses incorporating epitopes of Outer Membrane Protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa. Behring Inst. Mitt. 1997. 98:291-301.
46. Mansouri E, Gabelsberger J, Knapp B, Hundt E, Lenz U, Hungerer K, Gilleland HE Jr, Staceck J, Domdey H y von Specht B. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 1999. 67:1461-70.
47. Chen TY, Shang HF, Chen TI, Lin CP, Hui CF y Hwang J. Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection. Appl Microbiol Biotechnol. 1999.52:524-33.
48. Lee NG, Jung SB, Ahn BY, Kim YH, Kim JJ, Kim IS, Yoon SM, Nam SW, Kim HS and Park WJ. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine. 2000; 18(18):1952-61.
49. Lee NG, Ahn BY, Jung SB, KimYG, Kim HS y Park WJ. Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans. FEMS Immunology and Medical Microbiology. 2000. 27(1):79-85.
50. Denis-Mize KS, Price BM, Baker NR y Galloway DR. Analysis of immunization with DNA encoding Pseudomonas aeruginosa Exotoxin A. FEMS Immunol Med Microbiol. 2000; 27(2): 147-54.
51. Satczek J, Bendahmane M, Gilleland LB, Beachy RN y Gilleland HE Jr. Immunization with a chimerical tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P aeruginosa. Vaccine. 2000. 18:2226-74.
52. Shiau JW, Tang TK, Shih YL, Tai C Sung YY, Huang JL y Yang HL. Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication. Vaccine. 2000. Dec 8;19(9-10): 1106-12.
53. Bennet-Guerrero E, McIntosh TJ, Barclay GR, Snyder DS, Gibbs RJ, Mythen MG y Poxton IR. Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. Infect. Immun. 2000; 68(11):6202-08.
54. Hertle R, Mrsny R y Fitzgerald D. Dual-function vaccine for Pseudomonas aeruginosa: Characterization of chimerical Exotoxin A-pilin protein. Infect. Immun. 2001; 69(11): 6962-69.
55. Kikuchi T, Hackett NR y Crystal RG. 2001. Crossstrain protection against clinical and laboratory strains of Pseudomonas aeruginosa mediated by dendritic cells genetically modified to express CD40 ligand and pulsed with specific strains of Pseudomonas aeruginosa. Hum Gene Ther 12(10): 1251-63.
56. Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J y Gilleland JR. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against Outer Membrane Protein F (OprF) of Pseudomonas aeruginosa. Infect. Immun. 2001; 69(5):3510-15.
57. Price BM, Barten Legutki B, Galloway DR, von Specht BU, Gilleland LB Gilleland HE Jr. y Staczek J. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol Med Microbiol. 2002; 33(2-3):89-99.
58. Priebe GP, Brining M, Hatano K, Grout M, Coleman F, Pier GB y Golberg JB. Construction and characterization of a live attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect. Immun. 2002;70(3):1507-17.
59. Priebe GP, Meluleni GJ, Coleman FT, Goldberg J y Pier GB. 2003. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal inmunization with a live attenuated aroA deletion mutant. Infect. Immun 71(3):1453-61.
60. Nuriddinova NR, Ivanova LE, Sheremet’ev NN. y Garib Flu. 2002. Pseudomonas aeruginosa vaccine on the basis of antigens isolated from the supernant of culture media K-4. Zh Mikrobiol Epidemiol Immunobiol 4:40-3.
61. Ansoury E, Blome-Eberwein S, Gabelsberger J, Germann G and y Specht BU. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burns patients. FEMS Immunolol Med Microbiol. 2003; 37(2-3): 161-6.
62. Staczek J, Gilleland LB, van der Heyde HC y Gilleland HE. DNA vaccines against chronic lung infection by Pseudomonas aeruginosa. FEMS Immunol Med Microbiol. 2003; 37(2-3):147-53.
63. Teilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M y Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoide exopolisaccharide-alginate conjugate vaccine. Infect Immun. 2003; 71(7):3875-84.
]]>